SYGNIS AG / Key word(s): Capital Increase
17.11.2015 12:09
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Ad hoc announcement according to § 15 WpHG
---------------------------------------------------------------------------
NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN USA, CANADA, JAPAN
AND AUSTRALIA
SYGNIS AG plans to issue new shares to finance further growth and
commercialization of proprietary product Portfolio
- Cash capital increase by way of a rights offering of up to 3,855,694
new shares and targeted gross proceeds of EUR 6.7 million
- Subscription price per new share is EUR 1.90
- Proceeds used to progress the product portfolio, commercialization of
the product pipeline and expansion of customer base worldwide and other
purposes
- Major shareholder Genetrix S.L., Spain, committed to contribute
EUR 600,000 in kind by swapping its shareholder loan into equity
Madrid, Spain and Heidelberg, Germany, November 17, 2015 - SYGNIS AG
(Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today resolved, with
the approval of the Supervisory Board, to increase the Company's share
capital by up to EUR 3.9 million by issuing up to 3,855,694 new shares in
order to finance the expansion of its commercialization activities,
especially to the US, among other things. To this end, the Company is
planning a cash capital increase by way of a rights offering for existing
shareholders. A total of up to approx. 3.9 million new shares will be
offered for subscription. An oversubscription is possible. Any new shares
not subscribed for will be offered for sale to selected qualified investors
in private placements. The Management Board and Supervisory Board of SYGNIS
AG today resolved that a tranche of these new shares, valued at approx.
EUR 600,000 will be issued as a capital increase against contributions in
Kind in order to swap a substantial portion of an existing loan from major
shareholder Genetrix S.L., Spain, into equity.
Capital increase by way of a rights offering and against contributions in
kind:
SYGNIS AG intends to increase its share capital from EUR 13,494,934.00
composed of 13,494,934 no-par value bearer shares, to up to EUR
17,350,628.00, composed of up to 17,350,628 shares, while partially
utilising authorized capital.
With the rights issue, the share capital of the Company will be increased
by up to EUR 3,855,694.00 in return for cash contributions and
contributions in kind by up to 3,855,694 new no-par value bearer shares,
each with a notional par value of EUR 1.00. The new shares (Offer Shares)
will be offered to existing shareholders through indirect pre-emptive
rights by Small & Mid Cap Investmentbank AG (Munich, Germany). The
subscription ratio is 7:2, thus seven existing shares entitle the holder to
subscribe for two new shares. An oversubscription is possible. There shall
be no organized trading in subscription rights. The subscription price per
new share is EUR 1.90. Any new shares not subscribed in the offering will
be offered for sale in private placements to selected qualified investors
after the end of the subscription period. The Company aims to generate
gross proceeds of EUR 6.7 million from the cash capital increase, not
including the EUR 0.6 million loan contribution. Generated proceeds will be
used to progress the product portfolio, for further commercialization of
the existing products, and to grow and expand the customer base worldwide,
particularly in the US.
For further details on the rights issue, please see the subscription offer
provisionally planned to be published in the electronic Federal Gazette on
20 November 2015 and on the website of SYGNIS AG (www.sygnis.com). The
securities prospectus will be published under www.sygnis.com/investors.
**** End of ad hoc announcement ****
For further information please contact:
SYGNIS AG MC Services AG
Pilar de la Huerta Raimund Gabriel
CEO/CFO Managing Partner
Phone: +34 91 192 36 50 Phone: +49 89 210228 30
Email: pdelahuerta@sygnis.com Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS, headquartered in Germany and Spain, specializes on the development
and commercialization of innovative products for DNA amplification and
sequencing. Based on its proprietary technologies, SYGNIS has developed a
commercial product portfolio addressing key challenges in the fast growing
fields of molecular biology and next generation sequencing applications.
Key products include the TruePrime(TM) product line and SensiPhi(R),
licensed to an industry leading partner, for whole genome DNA amplification
and sequencing as well as the SunScript(TM) Reverse Transcriptase product
family to convert genetic information from RNA molecules back to DNA.
SYGNIS AG is listed at the German Stock Exchange in the Prime Standard
segment (Ticker: LIO1; ISIN: DE000A1RFM03).
### This document is not a securities prospectus and the information
contained therein does not constitute an offer to sell or a solicitation of
an offer to purchase any securities of SYGNIS AG in Federal Republic of
Germany nor under any other jurisdiction, in particular not where such kind
of offer or solicitation is prohibited or lacks the required permission.
Potential investors in securities of SYGNIS AG are asked to familiarize
themselves with and to observe the respective restrictions.
A decision to invest in the securities of SYGNIS AG should only be made on
the basis of the securities prospectus detailing the public offering of
securities of SYGNIS AG in the Federal Republic of Germany, which, subject
to the approval of the German Federal Financial Supervisory Authority
(BaFin) is anticipated to be published under www.sygnis.com/investors.
The information in this document may not be disseminated outside the
Federal Republic of Germany in particular not in the United States, to US
Persons (as defined in regulation S of the US Securities Act of 1933) or to
publications with a general circulation in the United States with the
exception of a such disclosures or announcements outside the Federal
Republic of Germany which have to be made under the respective mandatory
law. Any person who fails to comply with these restrictions may violate the
security laws of certain jurisdictions, in particular of the United States.
Securities in SYGNIS AG are not publicly offered outside the Federal
Republic of Germany. ###
17.11.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: SYGNIS AG
Waldhofer Str. 104
69123 Heidelberg
Germany
Phone: +49 (0) 6221 3540 125
Fax: +49 (0) 6221 3540 127
E-mail: investors@sygnis.com
Internet: www.sygnis.com
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: SYGNIS AG plans to issue new shares to finance further growth and commercialization of proprietary product portfolio
| Source: EQS Group AG